September 2016

Afrezza: Treating Diabetes in a Physiologic Manner

September 16, 2016

Evidence-Based Diabetes Management

Professor R. Keith Campbell, MBA, BPharm, CDE, now retired from Washington State University College of Pharmacy, highlights the clinical advantages of Afrezza based on the evidence as well as his personal perspective.

Patients Report Barriers to Getting Afrezza, but A1C Results Are Worth It

September 16, 2016

Evidence-Based Diabetes Management

Gaining access to Afrezza can mean battling with an insurer to cover it. Sometimes the first hurdle is getting a doctor to write a prescription, according to those who've been through the process.

Intarcia Poised to Seek FDA Approval for ITCA 650 After Positive A1C, CV Results

September 19, 2016

Evidence-Based Diabetes Management

Officials say the company will file with FDA some time in the third quarter of 2016 to begin the approval process for the novel delivery system that brings a continuous, microscopic dose of exenatide to patients with type 2 diabetes.

Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials

September 20, 2016

Evidence-Based Diabetes Management

Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.

As Metformin Combinations Proliferate, Questions Arise About Value

September 21, 2016

Evidence-Based Diabetes Management

For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.